MFC Co Ltd
432980
Company Profile
Business description
MFC Co Ltd is engaged in the development and manufacturing of raw pharmaceutical ingredients or materials. The company utilizes basic technologies such as organic synthesis and mass production technology, new crystallization technology to develop and mass-produce active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials (Pharmaceutical Ingredients (PI)) for production.
Contact
35, Cheongwon Industrial Complex 7-gil
Mado-myeon, 1453 Cheongwon-ri
Hwaseong-si
Gyeonggi-do
Seoul
KORT: +82 3180598293
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
65
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,387.34 | 60.09 | -0.12% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,378.14 | 90.34 | -0.37% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,101.27 | 24.79 | -0.35% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |